Table 2

Adverse events and second surgical interventions (n=225)

N (%)
Adverse events
 Microstent obstruction23 (10.2)
 IOP ≥10 mm Hg vs baseline20 (8.9)*
 Retinal complication10 (4.4)
 Loss of ≥2 lines of BCVA6 (2.7)
 Visual field loss4 (1.8)
 CyPass endothelial touch4 (1.8)
 Hyphema3 (1.3)
 Dry eye syndrome3 (1.3)
 Anterior chamber inflammation/uveitis2 (0.9)
 CyPass malposition2 (0.9)
 Hypotony1 (0.4)
 Conjunctivitis1 (0.4)
 Herpes keratitis1 (0.4)
 Band keratopathy1 (0.4)
 Focal corneal stromal oedema1 (0.4)
 Progression of corneal oedema1 (0.4)
 Opacification of anterior lens capsule1 (0.4)
 Plateau iris syndrome1 (0.4)
Secondary surgical interventions
 Secondary glaucoma surgery71 (31.6)†
  Trabeculectomy33 (14.7)
  Second microstent implantation13 (5.8)
  Cyclophotocoagulation10 (4.4)
  Tube/shunt implant5 (2.2)
  Deep sclerectomy4 (1.8)
  Other MIGS implant4 (1.8)
  Laser (trabeculoplasty or iridotomy)3 (1.3)
 Microstent obstruction lysis3 (1.3)
 Microstent repositioning2 (0.9)
 Microstent explantation2 (0.9)‡
 Cataract surgery19 (8.4)
 Other8 (3.6)
  • *Including 11 eyes that were phakic and 9 that were pseudophakic after CyPass implantation. Of the 11 phakic eyes, 1 had a history of narrow angle glaucoma, 1 had a history of secondary open angle glaucoma and 1 had undergone previous incisional glaucoma surgery. Of the nine pseudophakic eyes, six had undergone a previous glaucoma procedure, including four with previous incisional glaucoma surgery, with one of the latter having a history of congenital glaucoma.

  • †Including one eye that underwent two secondary glaucoma surgeries within 1 month, laser peripheral iridotomy and trabeculoplasty .

  • ‡Including from one eye with persistent corneal oedema and from one eye in conjunction with trabeculectomy for additional IOP control.

  • §

  • BCVA, best-corrected visual acuity; IOP, intraocular pressure; MIGS, minimally invasive glaucoma surgery.